Insights

The active pharmaceutical ingredient gets all the attention. Patent cliffs, IND filings, NDA approvals, blockbuster valuations — the API is […]

Every excipient supplier tracks global market size. Few track which drugs they are actually inside. That gap between macro estimates

How the five judges who control half of all ANDA litigation are reshaping patent strategy, generic timelines, and drug revenue

Between 2025 and 2030, roughly $400 billion in annual pharmaceutical revenue becomes legally contestable. That figure is not a projection

The global generic drug market is not growing uniformly. It is concentrating. Between 2025 and 2030, branded drugs accounting for

Why a 20-Year Patent Rarely Means 20 Years of Revenue The statutory term creates a false ceiling. The effective commercial

For pharma IP teams, portfolio managers, R&D leads, and institutional investors assessing Russia exposure in 2025-2030. The Rouble Economy: Why

The “patent death squad” label has haunted PTAB since 2012. The actual data tells a different story — one where

Combination drugs — pairing a biologic with a small molecule — are among the most commercially valuable assets in pharma.